Needham & Company
View Older Stories
-
EU Approval a 'Clear Positive' for Dendreon (DNDN) - Needham & Company
-
Pre-Open Stock Movers 8/23: (RENN) (MSFT) (UEPS) Higher; (DLLR) (ARO) (P) Lower (more...)
-
Notable 52-Week Highs and Lows of the Day 08/12: (SIRI) (NPSP) (KKD) High; (VICL) (ECTY) (DNDN) Low
-
Notable Analyst Rating Changes 11/12: (SQNM) (DIS) (KLAC) Upgraded; (GRMN) (JCP) (SD) Downgraded
-
StreetInsider.com Pre-Open Movers 11/12: (TIE) (JEF) (GILD) Higher; (CLVS) (STSI) (GRMN) Lower (more...)
-
Needham & Company Starts Dendreon (DNDN) at Buy
-
Pre-Open Movers 9/6: (OREX) (MW) (CALL) Higher; (OCZ) (PAY) (WCRX) Lower (more...)
-
Notable Analyst Rating Changes 05/23: (SBUX) (AMAT) (WMB) Upgraded; (NDAQ) (PSO) (ARBA) Downgraded
-
Notable Analyst Rating Changes 05/08: (VRTX) (XCO) (EA) Upgraded; (EP) (BP) (AMX) Downgraded
-
Morning Movers 02/01: (COCO) (MGAM) (KTCC) (RSYS) Higher; (IXYS) (JDAS) (KWK) Lower
-
Needham & Company 2012 Biotech Preview
-
Notable Analyst Rating Changes 11/11: (LSCC) (GNW) (DNDN) Upgraded; (CAG) (BRLI) (FSLR) Downgraded
-
Notable Analyst Rating Changes 09/16: (EBAY) (LYG) (REV) Upgraded; (RIMM) (ADBE) (SSYS) Downgraded
-
Unusual 11 Mid-Day Movers 08/04: (WWWW) (ATSG) (EM) Higher; (DNDN) (AIB) (NCIT) Lower
-
Notable 52-Week Highs and Lows of the Day 08/04: (KFT) (AUY) (CBOU) High; (DNDN) (PMI) (ENTR) Low
-
Morning Movers 08/04: (WWWW) (SRDX) (ATSG) (LHCG) Higher; (DNDN) (ENTR) (NCIT) (GTIV) (CLWR) Lower
-
Notable Analyst Rating Changes 08/04: (EMC) (MCD) (TIF) Upgraded; (DNDN) (WFR) (WLT) Downgraded
-
UPDATE - Needham & Company downgrades Dendreon (DNDN) from Buy to Hold; Strong Science, Modest Adoption but Lowering our PROVENGE Sales Ests Given N-T Hurdles
-
Needham & Company Downgrades Dendreon (DNDN) to Hold
-
Needham & Company Reiterates a 'Buy' on Dendreon (DNDN); Three Events Help Facilitate the One Goal of Increasing PROVENGE Sales
-
Needham & Company Maintains a 'Buy' on Dendreon (DNDN); ASCO Mtg Presentations Highlight PROVENGE Clinical Benefits Beyond Overall Survival
-
Needham & Co Highlights Seattle Genetics (SGEN), Pharmacyclics (PCYC), and Dendreon (DNDN) Ahead of ASCO
-
Needham & Company Reiterates a 'Buy' on Dendreon (DNDN); Company Management Executing on Sales/Manufacturing Plans to Expand PROVENGE Use
-
Needham & Company on Biotechnology & Life Sciences: Oncology / Hematology Review from the 2011 Needham Healthcare Conference
-
Needham & Company Maintains a 'Buy' on Dendreon (DNDN); Did You Get the Memo? CMS Supports the Coverage of PROVENGE for On-Label Use
-
Needham & Company Reiterates a 'Buy' on Dendreon (DNDN); PROVENGE Marches On, with Manufacturing Plans on Schedule
-
Needham & Company reiterates a 'Buy' on Dendreon (DNDN); Why Wait? Early New Year Plans to Expand PROVENGE Marketing in the US Alongside Expanded Manufacturing Capacity
-
Needham & Company Reiterates a 'Buy' on Dendreon (DNDN); PROVENGE Demand > Supply, Manufacturing on Track, Reimbursement Concerns Eased
-
Analysts Remain Bullish on Dendreon (DNDN) Following Positive MEDCAC Review
-
Needham & Company Reiterates a 'Buy' on Dendreon (DNDN); Clear Messages Emerged That On-Label PROVENGE Use Consistent with Survival Benefit
-
Needham & Company Reiterates a 'Buy' on Dendreon (DNDN); Potential Product Revenue and Manufacturing Build-Out
-
Needham & Company Reiterates a 'Buy' Rating Dendreon (DNDN); 2Q10 Earnings Preview
-
Needham & Company Maintanis a 'Buy' on Dendreon (DNDN); Raises PT to $62
-
Wall Street Giddy About Dendreon (DNDN) After Provenge Approval; Where Are Shares Headed?
-
Needham & Company Raises Price Target On Dendreon (DNDN) to $62
-
Notable Analyst Rating Changes 04/14: AIB, ERIC, MCD, CREE Upgraded; POT/MOS, TWC/DTV, DNDN, NOK Downgraded
-
Needham & Company Says Updated PROVENGE Data from Dendreon (DNDN) "Further Outline the Robustness"
-
Notable Analyst Rating Changes 1/7: BAC, SHLD, THC, IT, ZUMZ, CITP Upgraded; RAI, AA, RAD, WEN, BEXP Downgraded
-
Dendreon (DNDN) Prices 15M Common Offering at $24.75/Share
-
Needham Comments on "Who's Next" In Biotech After Bristol-Myers (BMY) Buys Medarex (MEDX)
-
Needham Discusses Next Steps For Dendreon's (DNDN) PROVENGE
-
Dendreon (DNDN) Sees Continued Upside On 'Table-Pounding' Analyst Comments
-
Needham Upgrades Dendreon (DNDN) To Buy, With 'Street High' $38 Price Target
-
Needham & Co Positive About Dendreon (DNDN) PROVENGE Results, Maintains Hold On Valuation